Over the past number of years there has been an undeniable change within the pharmaceutical sector due to the much debated and discussed “patent cliff”.  For some big Pharma brands, the lack of a significant R&D pipeline has been compounded by a lack of a lean manufacturing mind-set, which has resulted in expensive and uncompetitive manufacturing costs. But now it seems that the tide is turning.